{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:53:08Z","timestamp":1774885988915,"version":"3.50.1"},"reference-count":33,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,2,9]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Chronic scleritis poses a diagnostic and therapeutic challenge with multiple mimickers, underlying autoimmune conditions, diverse presentations and variable course. Treatment for mild forms includes topical corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs). For long-term control in patients with inadequate responses to steroids and NSAIDs, immunomodulators are employed. While oral cyclosporine has been used for inflammatory ocular conditions, research on topical cyclosporine for scleritis is limited. We present two cases: a man in his early 60s and a women in her late 20s, both with chronic, bilateral, intrapalpebral nodular scleritis with the clinical appearance of an inflamed pinguecula. After an initial poor response to conventional treatments, both patients responded positively to cyclosporine 0.05% ophthalmic emulsion as long-term monotherapy, likely due to cyclosporine\u2019s inhibitory effects. These outcomes suggest topical cyclosporine as an effective additive therapy to steroids to maintain quiescence for this particular subset of nodular scleritis, especially when traditional therapies are inadequate.<\/jats:p>","DOI":"10.1136\/bcr-2024-264327","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:55:46Z","timestamp":1740077746000},"page":"e264327","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Use of cyclosporine A 0.05% ophthalmic emulsion for a distinctive intrapalpebral phenotype of anterior scleritis"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-3571","authenticated-orcid":false,"given":"Jason Rafael","family":"Grullon","sequence":"first","affiliation":[{"name":"SUNY Upstate Medical University Norton College of Medicine, Syracuse, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8045-8358","authenticated-orcid":false,"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, SUNY Upstate Medical University, Syracuse, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Codrin E","family":"Iacob","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-5811","authenticated-orcid":false,"given":"Robert","family":"Swan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, SUNY Upstate Medical University, Syracuse, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"2025082703260414000_18.2.e264327.1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/APO.0000000000000341","article-title":"Current Approach for the Diagnosis and Management of Noninfective Scleritis","volume":"10","author":"Dutta Majumder","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2025082703260414000_18.2.e264327.2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0454","article-title":"Therapy Insight: scleritis and its relationship to systemic autoimmune disease","volume":"3","author":"Smith","year":"2007","journal-title":"Nat Rev Rheumatol"},{"key":"2025082703260414000_18.2.e264327.3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/09273948.2013.854394","article-title":"Clinical characteristics of scleritis and episcleritis: results from the pacific ocular inflammation study","volume":"22","author":"Homayounfar","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"2025082703260414000_18.2.e264327.4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.41709","article-title":"Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Population-Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immune-Mediated Inflammatory Disease","volume":"73","author":"Braithwaite","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025082703260414000_18.2.e264327.5","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13761"},{"key":"2025082703260414000_18.2.e264327.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2010.04.003"},{"key":"2025082703260414000_18.2.e264327.7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/09273948.2023.2191712","article-title":"Therapeutic Outcomes of Non-Infectious Scleritis Treated with Tumor Necrosis Factor-Alpha Inhibitors","volume":"32","author":"Brown","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"2025082703260414000_18.2.e264327.8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12016-016-8582-3","article-title":"The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review","volume":"52","author":"Chighizola","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025082703260414000_18.2.e264327.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001040","article-title":"Steroid-sparing effect of ciclosporin A 1 mg\/mL: 5-year case series of 107 children and young people with vernal keratoconjunctivitis","volume":"7","author":"Dahlmann-Noor","year":"2022","journal-title":"BMJ Open Ophth"},{"key":"2025082703260414000_18.2.e264327.10","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.9.743"},{"key":"2025082703260414000_18.2.e264327.11","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.75.6.340"},{"key":"2025082703260414000_18.2.e264327.12","first-page":"1358","article-title":"Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis","volume":"19","author":"McCarthy","year":"1992","journal-title":"J Rheumatol"},{"key":"2025082703260414000_18.2.e264327.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.08.010"},{"key":"2025082703260414000_18.2.e264327.14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000430490","article-title":"Systemic Cyclosporine Therapy for Scleritis: A Proposal of a Novel System to Assess the Activity of Scleritis","volume":"6","author":"Aoki","year":"2015","journal-title":"Case Rep Ophthalmol"},{"key":"2025082703260414000_18.2.e264327.15","article-title":"Cyclosporine: a review","volume":"2012","author":"Tedesco","year":"2012","journal-title":"J Transplant"},{"key":"2025082703260414000_18.2.e264327.16","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15490","article-title":"A systematic review of the efficacy and safety of topical cyclosporine in dermatology","volume":"35","author":"Sadeghi","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025082703260414000_18.2.e264327.17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003226-198501000-00002","article-title":"Local treatment of necrotizing scleritis with cyclosporin A","volume":"4","author":"Hoffmann","year":"1985","journal-title":"Cornea"},{"key":"2025082703260414000_18.2.e264327.18","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100010022009"},{"key":"2025082703260414000_18.2.e264327.19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/ICL.0b013e3181b4d135","article-title":"Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature","volume":"35","author":"Gumus","year":"2009","journal-title":"Eye Contact Lens"},{"key":"2025082703260414000_18.2.e264327.20","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199309000-00008"},{"key":"2025082703260414000_18.2.e264327.21","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.60.3.163"},{"key":"2025082703260414000_18.2.e264327.22","unstructured":"Schonberg S , Episcleritis STJ . StatPearls. Treasure Island (FL): StatPearls Publishing LLC, 2024."},{"key":"2025082703260414000_18.2.e264327.23","unstructured":"Lagina A , Scleritis RK . StatPearls. Treasure Island (FL): StatPearls Publishing LLC, 2024."},{"key":"2025082703260414000_18.2.e264327.24","unstructured":"Somnath A , Pinguecula TK . StatPearls. Treasure Island (FL): StatPearls Publishing LLC, 2024."},{"key":"2025082703260414000_18.2.e264327.25","doi-asserted-by":"crossref","unstructured":"Abdel-Aty A , Gupta A , Del Priore L , et al . Management of noninfectious scleritis. Ther Adv Ophthalmol 2022;14. doi:10.1177\/25158414211070879","DOI":"10.1177\/25158414211070879"},{"key":"2025082703260414000_18.2.e264327.26","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2019.20025","article-title":"Treatment of chronic non-infectious uveitis and scleritis","volume":"149","author":"Rossi","year":"2019","journal-title":"Swiss Med Wkly"},{"key":"2025082703260414000_18.2.e264327.27","doi-asserted-by":"crossref","first-page":"108078","DOI":"10.1016\/j.exer.2020.108078","article-title":"Current insights in the pathogenesis of scleritis","volume":"197","author":"Vergouwen","year":"2020","journal-title":"Exp Eye Res"},{"key":"2025082703260414000_18.2.e264327.28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/OPTH.S1409","article-title":"Treatment of chronic dry eye: focus on cyclosporine","volume":"2","author":"Kymionis","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"2025082703260414000_18.2.e264327.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2009.02.002"},{"key":"2025082703260414000_18.2.e264327.30","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"2025082703260414000_18.2.e264327.31","first-page":"2254","article-title":"Silent Crohn\u2019s Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization","volume":"21","author":"Click","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2025082703260414000_18.2.e264327.32","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/rheumatology\/ket001","article-title":"What can asymptomatic hyperuricaemia and systemic inflammation in the absence of gout tell us?","volume":"52","author":"Inaba","year":"2013","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025082703260414000_18.2.e264327.33","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199808)41:8<1481::AID-ART19>3.0.CO;2-O"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-264327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:26:18Z","timestamp":1756290378000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-264327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,20]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bcr-2024-264327"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-264327","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}